The molecular docking analysis also showed that our proposed drug molecules significantly bind to the previously suggested BC-causing top-ranked HubGs (AURKA, BUB1, FN1, TPX2, CDC20, CCNA2, CCNB1, BUB1B, CDK1 and TOP2A)-mediated receptor proteins. This evidence concerns the gene BUB1B and breast cancer.